Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pds.4247 http://scihub22266oqcxt.onion/10.1002/pds.4247 C5575476!5575476!28653790     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28653790.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pharmacoepidemiol+Drug+Saf 2017 ; 26 (8): 1006-10 Nephropedia Template TP {{tp|p=28653790|t=2017. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real?world use |pdf=|usr=}}{{28653790}} gab.com Text vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real world use JO: Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=28653790 #FOAvip Purpose: vigiRank is a data?driven predictive model for emerging safety signals. In addition to disproportionate reporting patterns, it also accounts for the completeness, recency, and geographic spread of individual case reporting, as well as the availability of case narratives. Previous retrospective analysis suggested that vigiRank performed better than disproportionality analysis alone. The purpose of the present analysis was to evaluate its prospective performance. Methods: The evaluation of vigiRank was based on real?world signal detection in VigiBase. In May 2014, vigiRank scores were computed for pairs of new drugs and WHO Adverse Reaction Terminology critical terms with at most 30 reports from at least 2 countries. Initial manual assessments were performed in order of descending score, selecting a subset of drug?adverse drug reaction pairs for in?depth expert assessment. The primary performance metric was the proportion of initial assessments that were decided signals during in?depth assessment. As comparator, the historical performance for disproportionality? guided signal detection in VigiBase was computed from a corresponding cohort of drug?adverse drug reaction pairs assessed between 2009 and 2013. During this period, the requirement for initial manual assessment was a positive lower endpoint of the 95% credibility interval of the Information Component measure of disproportionality, observed for the first time. Results: 194 initial assessments suggested by vigiRank's ordering eventually resulted in 6 (3.1%) signals. Disproportionality analysis yielded 19 signals from 1592 initial assessments (1.2%; P < .05). Conclusions: Combining multiple strength?of?evidence aspects as in vigiRank significantly outperformed disproportionality analysis alone in real?world pharmacovigilance signal detection, for VigiBase. Twit Text FOAVip vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real world use ????Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=28653790 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28653790 #FOAvip English Wikipedia <ref>{{Cite pmid|28653790}}</ref> vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real?world use #MMPMID28653790 Caster O; Sandberg L; Bergvall T; Watson S; Norén GN Pharmacoepidemiol Drug Saf 2017[Aug]; 26 (8): 1006-10 PMID28653790show ga Purpose: vigiRank is a data?driven predictive model for emerging safety signals. In addition to disproportionate reporting patterns, it also accounts for the completeness, recency, and geographic spread of individual case reporting, as well as the availability of case narratives. Previous retrospective analysis suggested that vigiRank performed better than disproportionality analysis alone. The purpose of the present analysis was to evaluate its prospective performance. Methods: The evaluation of vigiRank was based on real?world signal detection in VigiBase. In May 2014, vigiRank scores were computed for pairs of new drugs and WHO Adverse Reaction Terminology critical terms with at most 30 reports from at least 2 countries. Initial manual assessments were performed in order of descending score, selecting a subset of drug?adverse drug reaction pairs for in?depth expert assessment. The primary performance metric was the proportion of initial assessments that were decided signals during in?depth assessment. As comparator, the historical performance for disproportionality? guided signal detection in VigiBase was computed from a corresponding cohort of drug?adverse drug reaction pairs assessed between 2009 and 2013. During this period, the requirement for initial manual assessment was a positive lower endpoint of the 95% credibility interval of the Information Component measure of disproportionality, observed for the first time. Results: 194 initial assessments suggested by vigiRank's ordering eventually resulted in 6 (3.1%) signals. Disproportionality analysis yielded 19 signals from 1592 initial assessments (1.2%; P < .05). Conclusions: Combining multiple strength?of?evidence aspects as in vigiRank significantly outperformed disproportionality analysis alone in real?world pharmacovigilance signal detection, for VigiBase. ävigiRank for statistical signal detection in pharmacovigilance: First (epmc).pdf DeepDyve Pubget Overpricing